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Background: First-degree relatives (FDRs) of women with PCOS are at increased risk for impaired insulin sensitivity
and diabetes mellitus. Glucose tolerant FDR have evidence of insulin resistance and hyperinsulinemia prior to
emergence of frank PCOS.
Aim: To study insulin dynamics parameters in the early adolescent FDR of women with PCOS.
Methods: This is a cross-sectional study involving 18 adolescents whose mothers or sisters had been diagnosed
with PCOS and 21 healthy, age-matched control adolescents without FDR. Subjects underwent anthropometric
measurements, steroid profiling and frequently sampled Intravenous Glucose Tolerance Test (IVGTT), Homeostasis
Model Assessment (HOMA) index, Glucose Disposal Index (GDI), Acute Insulin Response (AIR) and Quantitative
insulin sensitivity check index (QUICKI) were derived from IVGTT results.
Results: FDRs showed significantly higher mean HOMA and lower GDI. There were no differences in mean age or
BMI Z-score between the cohorts. No differences in sex steroids or AIR were identified between groups.
Conclusion: Female adolescent FDR of women with PCOS have higher HOMA index and lower QUICKI, reflecting
altered insulin sensitivity and lower GDI reflecting poorer beta-cell function. The presence of multiple risk factors for
type 2 diabetes suggests that aggressive screening of the early adolescent FDR of women with PCOS is indicated.
Keywords: PCOS, Insulin resistance, Insulin sensitivity, Anovulation, Hyperandrogenemia, Premature pubarche,
Diabetes mellitus, Beta cell functionIntroduction
POLYCYSTIC OVARY SYNDROME (PCOS) is an
endocrine-metabolic disorder, which is highly prevalent
(5–10%) in reproductive-age women [1-3]. PCOS is
characterized by hyperandrogenism [4,5]. The pheno-
typic characterization is heterogeneous; PCOS can mani-
fest in the prepubertal years as premature pubarche [6];
hirsutism, acne and anovulatory cycles may remain clin-
ically silent until late adolescence. Peripheral insulin re-
sistance plays a key role in the pathogenesis of this* Correspondence: Tenlana@aol.com
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reproduction in any medium, provided the orsyndrome. It has been suggested that insulin excess facil-
itates ovarian and/or adrenal hyperandrogenism [7-10].
Insulin resistance in PCOS women has long-term health
consequences, predisposing to type 2 diabetes mellitus,
cardiovascular disease and pregnancy-associated disor-
ders like infertility, miscarriage, premature labor and
gestational diabetes [11-15].
Female first-degree relatives (FDRs) of PCOS-affected
women are at higher risk for developing PCOS symp-
toms [16]. FDRs are also at higher risk of developing the
endocrine and metabolic co-morbidities of PCOS, such
as obesity, insulin resistance and impaired insulin sensi-
tivity, hyperlipidemia and metabolic syndrome[17-21].
An abundant literature supports familial clustering of
hyperandrogenemia in PCOS women, consistent with aal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ies have shown an increased prevalence of hyperandro-
genism and insulin resistance in adult FDRs of PCOS
[16].
Despite the alarming increase in the prevalence of type
2 diabetes in children, and efforts to identify risk factors
for the development of this disease in children studies of
glucose homeostasis in pediatric FDRs of PCOS, have
not been performed. In the present study we assessed
the insulin secretion (β-cell function), insulin sensitivity,
adrenal and ovarian steroid levels in peri-pubertal daugh-
ters and sisters of women diagnosed with PCOS. Our pur-
pose was to determine the presence of early biochemical
changes in females at risk of PCOS before clinical mani-
festations occurred and to evaluate whether insulin resist-
ance or hyperandrogenemia occurs before in FDRs of
PCOS women. We performed IVGTT to more compre-
hensively study the insulin dynamics in this cohort, and
compared the results with those of an age- and weight-
matched group of controls who were daughters or sisters
of women without PCOS. The short version of IVGTT
provides enough testing points to calculate indexes to as-
sess insulin sensitivity and β-cell function. We also com-
pared the steroid levels in both groups to evaluate the
existence of the hormonal imbalance in FDRs. We
hypothesized that being an FDR of a PCOS conveys an in-
dependent risk for the development of type 2 diabetes in-




We studied 18 healthy premenarchal girls (mean age
of 11.6 ± 1.1 years, range 8–14) whose mothers or sis-
ters had been diagnosed with PCOS and were fol-
lowed in adult and pediatric endocrinology clinics at
Maimonides Medical Center, University of Sherbooke,
University of Chile, Vanderbilt University and Cedars-Sinai
Medical Center. All had been diagnosed with PCOS based
upon the National Institute of Child Health and Human
Development criteria for PCOS [23], including history of
documented chronic oligomenorrhea or amenorrhea and
hyperandrogenism, with the exclusion of secondary
causes. The anthropometric, insulin dynamics and steroid
data of FDR subjects was determined for NIH K23
HD040325, “Insulin Resistance in Adolescents at High
Risk for Polycystic Ovary Syndrome".
The control group consisted of 21 healthy premenarchal
girls (mean age of 12.1± 0.4 years, range 8–14) whose
mothers had no history of irregular menstrual cycles or
hirsutism. Children were recruited from a school-based
study that is part of Reduce Obesity and Diabetes (ROAD)
Project, a collaborative project between Maimonides
Medical Center and Columbia University Medical Center,Cohen Children’s Medical Center, Mount Sinai Medical
Center, Winthrop University Hospital and New York City
public schools. This ongoing project is supported by
Academy for Medical Development and Collaboration
(AMDeC). These children had no personal history of dia-
betes or family history of irregular menstruation, diabetes
or hirsutism.
First-degree relatives of PCOS women were recruited and
tested following approval from the Institutional Review
Boards at Cedars-Sinai Medical Center (Los Angeles),
Sherbrooke University (Sherbrooke, Canada), University
of Chile (Santiago, Chile), Vanderbilt University (Nashville,
TN), and Maimonides Medical Center (Brooklyn, New
York). The ROAD Project study was approved by the
Institutional Review Board for each participating hospital,
school boards and the Department of Health and
Education. Written informed consent was obtained from
all parents and assent from the peri-adolescent study
subjects.Study protocol
Assessment
All study subjects were either tested at Maimonides
Medical Center Clinic (MMCC), ROAD school based study
or at Cedars-Sinai Medical Center, Vanderbilt University,
University of Sherbrooke or University of Chile. Enrollees
presented after an overnight fast. A comprehensive medical
assessment and medical history were obtained, including a
personal and family history of type 2 diabetes, metabolic
syndrome or heart disease. Anthropometric measurements
included weight, height, body mass index (BMI), and waist
circumference (waist: midway between the lower rib margin
and the iliac crest). Age- and sex-specific BMI z-scores
were calculated by using National Center for Health
Statistics (NCHS) data [24]. Body fat composition was
determined by bioelectrical impedance (Body Fat Analyzer,
Model HBF-306, Omron, Gays Mills, WI). A Tanner stage
was assigned to each study subject based on levels of both
DHEAS and E2. No participants in the study were taking
medications known to affect either sex steroids or carbohy-
drate metabolism.IVGTT
Rapid frequently sampled intravenous glucose tolerance
testing (IVGTT) was performed on all FDRs [25]. Each
subject was given IV 25% Dextrose at 2 ml/Kg (max
25gm of Dextrose) delivered over 1 min, and blood was
drawn through the same butterfly needle for measure-
ments of serum glucose and insulin at 2, 3, 4 and 5 min
after glucose administration. Short version of IVGTT (5
point over 5 minutes versus 3 hr classic IVGTT) had
been chosen in control group because it was less time
consuming in the school-based study.
Table 1 Anthropometric characteristic of PCOS FDR and
Control Daughters (Cd)
FDR-PCOS (n= 18) Cd group (n = 21)
Age (yr) 11.6 ± 1.4 12. ± 0.8
BMI (kg/m2) 21.5 ± 3.5 21.5 ±3.2
BMI Z Score 1.01 ±0.85 0.93±0.9
Waist Circumference (cm) 72±10.9 76 ±8.7
Body Fat % 25±2.5 25.76±3.2
Data are presented as the mean ± SD. *P value <0.05.
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Additional baseline blood samples were obtained for de-
termination of DHEAS and Estradiol (E2).
Serum glucose was determined by the glucose hexoki-
nase procedure from Raichem. The intra- and interassay
coefficient of variation of this method was less than 3%.
Serum insulin was determined by a solid phase sandwich
immunoassay developed by Wallace/Perkin-Elmer. The
intra-assay coefficient of variation of this method is
3-6%. Serum assays for DHEAS and E2 were performed
by Labcorp Institute (Burlington, NC). Assay sensitivities
for DHEAS and E2 were 1.7 ng/dl, 10 pg/ml, respect-
ively. Intra- and interassay coefficients of variation were
7.9-9.8% for DHEAS and 97% for E2.Calculations
Insulin resistance was estimated by the Homeostasis Model
Assessment for Insulin Resistance (HOMA-IR), calculated
as [fasting insulin (μU/ml) x fasting glucose (mg/dl)]/405]
[26] and insulin sensitivity was estimated by Quantitative
Insulin Sensitivity Check Index (QUICKI), calculated
as [1/(log fasting insulin μU/ml) + log (fasting glucose
mg/dl)] [27]. The acute insulin response (AIRg) was calcu-
lated as mean incremental rise in plasma insulin at 3 and
5 min after IV glucose. Pancreatic β-cell function was
assessed by calculating the Glucose Disposal index as
[log10 (AIRg x fasting glucose concentration/fasting insu-
lin concentration)] [25,28].Statistical methods and analysis
Data are expressed as mean ± SD. Freidman’s repeated
measures ANOVA was used to compare variables (age,
BMI Z-score, HOMA, QUICKI, GDI, DHEAS, etc.)
within the same group. Comparisons of means between
the PCOS affected first-degree relatives group (PCOS-
FDR) and the control group were performed using the
Unequal Variance, Unequal Sample Size t-test. Regres-
sion analysis and Spearman correlations were used to
evaluate the relationship between the variables of interest.
Statistical analysis was performed using SPSS Statistics
17.0.Table 2 Biochemical characteristics in FDR-PCOS and
Control Daughters (Cd) groups
FDR-PCOS Group (n = 18) Cd Group (n = 21)
DHEA-S 63 (65) 99.5 (71)
AIRg 80 (54) 97 (43)
QUICKI 0.32 (0.03) * 0.35(0.02)
HOMA-IR 3.45 (1.7)* 2.04 (1.6)
GDI 2.6 (0.46) * 2.98 (0.27)
Data are presented as the mean ± SD. *P value <0.05.Results
Anthropometry and hormonal assay
There were no significant differences between the
PCOS-FDR and the control groups with respect to age,
BMI, BMI Z score, waist circumference or percent of
body fat (Table 1). There were no significant differences
in serum DHEA-S between groups. E2 levels were sig-
nificantly higher in PCOS-FDR group comparing to the
control group. Both groups had similar Tanner stage dis-
tributions, as a function of DHEA-S and E2 levels.IVGTT
The HOMA-IR ratio was significantly higher, and both
the QUICKI and GDI parameters were significantly
lower in the PCOS-FDR group compared to the control
group (Table 2). The HOMA-IR ratio findings were un-
changed even after segregating the PCOS-FDR and con-
trol groups according to Tanner stage. AIR was not
significantly different between groups.Discussion
The major findings of this study are that both decreased
insulin sensitivity and beta-cell function are evident in
premenarachal peripubertal female FDR’s of PCOS with-
out clinical or biochemical evidence of PCOS. These
data suggest that having a first-degree relative with
PCOS may be an independent risk factor for the devel-
opment of type 2 diabetes in childhood. The implication
is that FDR’s of PCOS should potentially be screened
more aggressively for pre-diabetic risk factors, including
obesity, hypertriglyceridemia, and a pro-inflammatory
state and should be considered an at-risk group in terms
of efforts to prevent the development of other risk fac-
tors. Finally, the detection of impaired glucose homeo-
stasis prior to the onset of hyperandrogenism is in
agreement with the hypothesis that hyperinsulinism is a
cause, rather than the result, of PCOS.
PCOS is likely the cumulative product of a number of
genetic, epigenetic, environmental factors and/or familial
habits [29]. PCOS may be inherited in an autosomal dom-
inant or X-linked dominant pattern [30-32]. Genome-wide
genetic and linkage studies have found associations
with PCOS for many genes including fibrillin-3, PPAR-γ
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and development of the characteristic syndrome may
occur in the absence of known mutation. In complex, het-
erogeneous conditions with variable presentation such as
PCOS, studies of first-degree relatives of affected females
may help to separate the biochemical contributions from
genetic and habitual influence.
Hyperandrogenism is the consistent finding in prior
studies of the adult relatives of PCOS women [22,37-39]
but the data on hyperandrogenism in peripubertal FDR is
scant. One study observed higher androgen levels in the
later stages of puberty (Tanner 4 and 5) in PCOS-FDR
subjects compared to control daughters [40], likely an ex-
pression of the normal maturation of the hypothalamic-
pituitary gonadal axis.
Many have proposed that hyperinsulinism is the fun-
damental pathophysiological event leading to ovarian
and/or adrenal production of excessive androgen [41].
Hyperandrogenism is the primary feature in the emer-
gence of PCOS [22,42]. In our study, significant differ-
ences in the androgen precursor DHEA-S between the
two groups were not detected.
Conversely, beta-cell function was impaired not only
in affected PCOS probands but also in their first-degree
relatives, regardless of whether PCOS or other metabolic
abnormalities were yet manifest. Prior reports of insulin
resistance and glucose insensitivity in first-degree rela-
tives utilized manipulation of the less informative oral
glucose tolerance test. A recent study demonstrated
hyperinsulinemia and increased ovarian volumes present
in PCOS daughters even prior to the onset of puberty,
the hyperinsulinemia persisting throughout pubertal de-
velopment. Other biochemical abnormalities of PCOS
emerge only in later puberty [40], suggesting that meta-
bolic disturbances are fundamental to establishment of
permanent states of androgen excess.
Frequently-sampled IVGTT is a well-validated method
of estimating insulin sensitivity and considered superior
to OGTT-derived measures of insulin dynamics [43-45]
as it allows determination of the glucose disposal index
(GDI), a highly sensitive reflection of the capacity of
pancreatic islets to compensate for lower insulin sensi-
tivity [46]. We utilized IVGTT to assess both glucose
tolerance and insulin resistance as well as the acute in-
sulin response and glucose disposition indices that better
define the beta-cell function.
Our data provides evidence of early development of insu-
lin resistance in the peripubertal first-degree female rela-
tives of women with PCOS. All three measures, QUICKI,
HOMA-IR and GDI, demonstrated lower insulin sensitivity
among PCOS first-degree relatives versus weight, Tanner,
age-matched controls without family history of PCOS, dia-
betes mellitus and hypertension. Perturbed beta-cell dys-
function and the resulting inadequate compensation fordeteriorating insulin sensitivity has been demonstrated in
the daughters of PCOS-affected women prior to puberty
and independently of body weight. Our findings suggest
that peripubertal insulin resistance (IR) even prior to bio-
chemical or clinically apparent androgen excess may also
be an early hallmark of risk for PCOS in the genetically vul-
nerable peri-adolescent population as well. This emphasizes
the necessity of early and ongoing biochemical monitoring
of relatives of women with PCOS, affording the opportunity
for both earlier diagnosis and therapeutic intervention to
prevent the long-term morbidity inherent in this disorder.
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